Literature DB >> 1724602

Changes in CSF neurotransmitters in infantile spasms.

P J Langlais1, M L Wardlow, H Yamamoto.   

Abstract

Cerebrospinal fluid (CSF) from 7 patients with infantile spasms (mean age: 6.7 months) was collected before and after treatment with adrenocorticotropic hormone (ACTH). The concentration of neurotransmitter metabolites was analyzed using high-performance liquid chromatography and compared to the metabolite concentration in the CSF from 7 age-matched controls (mean age: 6.1 months). Pretreatment levels of CSF 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid, 3-methoxy-4-hydroxyphenyl glycol (MHPG), and kynurenine were significantly lower in infantile spasm patients compared to controls. Following treatment, marked increases in 5-HIAA and decreases in kynurenine levels were observed in the CSF of the 5 infants whose seizures were eliminated or reduced by ACTH. In the 2 nonresponders 5-HIAA levels decreased. The level of MHPG was reduced slightly in 5 infants, including the 2 nonresponders, and was increased in 2 responders. CSF homovanillic acid levels increased in 4 infantile spasm infants and decreased in 3 following ACTH. These data demonstrate that the presence of seizures in infantile spasms is associated with a significant decrease in serotonergic activity and that elimination of seizures by ACTH is accompanied by increased serotonin turnover. The simultaneous increase of 5-HIAA and decrease of kynurenine, an alternate metabolite of tryptophan, suggests an underlying disturbance of tryptophan metabolism in infantile spasms. The possibility that elimination of seizures by ACTH may be related to decreased production of certain kynurenine metabolites, particularly quinolinic acid, is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724602     DOI: 10.1016/0887-8994(91)90028-j

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  7 in total

Review 1.  Inflammation in Epileptic Encephalopathies.

Authors:  Oleksii Shandra; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Adv Protein Chem Struct Biol       Date:  2017-02-28       Impact factor: 3.507

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 3.  Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Neurobiol Dis       Date:  2015-05-09       Impact factor: 5.996

4.  Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders.

Authors:  Elisa De Grandis; Mercedes Serrano; Belén Pérez-Dueñas; Aida Ormazábal; Raquel Montero; Edvige Veneselli; Mercè Pineda; Verónica González; Francesc Sanmartí; Carmen Fons; Anna Sans; Bru Cormand; Luis Puelles; Antonia Alonso; Jaime Campistol; Rafael Artuch; Angels García-Cazorla
Journal:  J Inherit Metab Dis       Date:  2010-09-18       Impact factor: 4.982

5.  Association of serotonin transporter polymorphisms with responsiveness to adrenocorticotropic hormone in infantile spasm.

Authors:  Xiu-Yu Shi; Li-Ping Zou; Guang Yang; Ying-Xue Ding; Bing He; Yan-Hong Sun; Fei-Yong Jia
Journal:  World J Pediatr       Date:  2013-06-17       Impact factor: 2.764

Review 6.  Prenatal corticosteroids modify glutamatergic and GABAergic synapse genomic fabric: insights from a novel animal model of infantile spasms.

Authors:  D A Iacobas; S Iacobas; T Chachua; C Goletiani; G Sidyelyeva; J Velíšková; L Velíšek
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

7.  Seizure modulation by the gut microbiota and tryptophan-kynurenine metabolism in an animal model of infantile spasms.

Authors:  Chunlong Mu; Anamika Choudhary; Shyamchand Mayengbam; Karlene T Barrett; Jong M Rho; Jane Shearer; Morris H Scantlebury
Journal:  EBioMedicine       Date:  2022-01-25       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.